Literature DB >> 10699994

Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer.

K Kaserer1, J Schmaus, U Bethge, B Migschitz, S Fasching, A Walch, F Herbst, B Teleky, F Wrba.   

Abstract

Immunohistochemistry (IHC) is a cheap and rapid method to detect p53 inactivation but the results are often discordant with gene mutation analysis. This study aimed to investigate whether there is a difference in the immunohistochemical staining patterns of p53-positive cells on comparing tumours with inactivating gene mutations with those without. Tissues of 142 colorectal cancers were investigated for p53 inactivation simultaneously by IHC and gene analysis using SSCP of exons 4-9 and sequencing. In addition, tumours were investigated immunohistochemically for the expression of mdm-2 protein, known to be transcriptionally transactivated by the wild-type (wt) p53 gene. p53-positive cells of tumours without detectable p53 gene mutations were microdissected using a PALM laser microscope system and subjected to p53 sequence analysis. Among the 142 cases of colorectal cancer (male/female=88/54; mean age 66a+/-11 years, range 24-90 years), 74% (n=105) of tumours were positive by p53 IHC and mutations in the p53 gene were found in 51% (73 patients). In 16% (12 patients) with mutations in the p53 gene, IHC for p53 was negative. In tumours with mutations in the p53 gene and positive p53 IHC, staining of all nuclei of the tumour was more frequently (57/61, 93%) found than in tumours without p53 gene mutations, where staining of scattered single cells was predominantly seen (29/44, 66%; p<0.0001). mdm-2 positivity (n=33) showed only staining of scattered single cells, predominantly (24/33, 82%; p<0.0001) in tumours without gene mutations. Single cell microdissection followed by mutation analysis of scattered p53-positive cells revealed no gene mutations. A scattered positive immunohistochemical reactivity of p53 in colorectal cancer cells might therefore represent a functionally active non-mutated p53 gene and should not be considered as a marker of gene mutation and inactivation. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699994     DOI: 10.1002/(SICI)1096-9896(200003)190:4<450::AID-PATH545>3.0.CO;2-8

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

1.  Glyoxalase I retards renal senescence.

Authors:  Yoichiro Ikeda; Reiko Inagi; Toshio Miyata; Ryoji Nagai; Makoto Arai; Mitsuhiro Miyashita; Masanari Itokawa; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2011-10-12       Impact factor: 4.307

2.  Mortalin is a prognostic factor of gastric cancer with normal p53 function.

Authors:  Koji Ando; Eiji Oki; Yan Zhao; Ayae Ikawa-Yoshida; Hiroyuki Kitao; Hiroshi Saeki; Yasue Kimura; Satoshi Ida; Masaru Morita; Tetsuya Kusumoto; Yoshihiko Maehara
Journal:  Gastric Cancer       Date:  2013-07-05       Impact factor: 7.370

3.  Long-lived intestinal tuft cells serve as colon cancer-initiating cells.

Authors:  C Benedikt Westphalen; Samuel Asfaha; Yoku Hayakawa; Yoshihiro Takemoto; Dana J Lukin; Andreas H Nuber; Anna Brandtner; Wanda Setlik; Helen Remotti; Ashlesha Muley; Xiaowei Chen; Randal May; Courtney W Houchen; James G Fox; Michael D Gershon; Michael Quante; Timothy C Wang
Journal:  J Clin Invest       Date:  2014-03       Impact factor: 14.808

4.  Correlation of p53 Overexpression with the Clinicopathological Prognostic Factors in Colorectal Adenocarcinoma.

Authors:  Vijaya Mysorekar; Adithi Raj; Smitha Shetty
Journal:  J Clin Diagn Res       Date:  2016-12-01

5.  Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas.

Authors:  Yuichi Kitagawa; Trisha A Unger; Shari Taylor; Richard A Kozarek; L William Traverso
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

6.  Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.

Authors:  Kenji Sugamura; John F Gibbs; Alan Belicha-Villanueva; Christopher Andrews; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Oncology       Date:  2008-08-20       Impact factor: 2.935

7.  p53 protein accumulation as a prognostic marker in sporadic colorectal cancer.

Authors:  Yuan-Tzu Lan; Shih-Ching Chang; Anna Fen-Yau Li; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Jen-Kou Lin
Journal:  Int J Colorectal Dis       Date:  2006-10-05       Impact factor: 2.796

8.  Biomarkers in precision therapy in colorectal cancer.

Authors:  Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-08-23

9.  Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer.

Authors:  Koji Ando; Eiji Oki; Hiroshi Saeki; Zhao Yan; Yasuo Tsuda; Gen Hidaka; Yuta Kasagi; Hajime Otsu; Hiroyuki Kawano; Hiroyuki Kitao; Masaru Morita; Yoshihiko Maehara
Journal:  Cancer Med       Date:  2014-10-30       Impact factor: 4.452

10.  The genomics of colorectal cancer: state of the art.

Authors:  Andrew D Beggs; Shirley V Hodgson
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.